What’s wrong in govt consulting industry for policies?

  Last week the famous whistle blower in Ranbaxy data fudging case wrote in Scroll that the Indian drug regulator is “inept” in regulating biosimilars, a new class of drugs that have come to dominate the market and will increasingly do so for the next decade.   Dinesh Thakur certainly has a point but it […]

Personalizing cancer care, one tumor at a time

When cancer knocks at one’s door, pretty much like a dreaded guest, one doesn’t know the extent of the dread immediately. As the guest settles in, the unpleasantness unravels. It’s somewhat similar feeling with cancer diagnosis. One doesn’t know if it’s a deadly form of cancer and in what stage; what will be the prognosis; […]

The many downsides and one upside of India’s clinical trials mess

  Hardly a week goes by when the term ˜clinical trial” is not in news, and unfortunately, in recent times, it’s been more for the wrong reasons. On January 9, Financial Times reported Novartis will face a criminal investigation for wrongful marketing practices of its popular blood pressure medicine Diovan. Then there was this detailed […]

The many downsides and one upside of India's clinical trials mess

  Hardly a week goes by when the term ˜clinical trial” is not in news, and unfortunately, in recent times, it’s been more for the wrong reasons. On January 9, Financial Times reported Novartis will face a criminal investigation for wrongful marketing practices of its popular blood pressure medicine Diovan. Then there was this detailed […]